Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Craig C Earle

Showing results (61-70 of 288) with videos related to

Pageof 29
Sort By:
Journal of Thoracic Disease|October 18, 2021
Second and later-line erlotinib use in non-small cell lung cancer: real world outcomes and practice patterns overtime in CanadaKirstin Perdrizet, Rinku Sutradhar, Qing Li, et al.
Journal of the American College of Surgeons|February 21, 2009
Impact of patient age and comorbidity on surgeon versus oncologist preferences for adjuvant chemotherapy for stage III colon cancerMonika K Krzyzanowska, Meredith M Regan, Mark Powell, et al.
Leukemia & Lymphoma|February 11, 2020
Healthcare utilization in patients with higher-risk MDS/low-blast count AML treated with azacitidine in the 'real-world'Lee Mozessohn, Matthew C Cheung, Nicole Mittmann, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 8, 2020
High-Cost Patients and Preventable Spending: A Population-Based StudyClaire de Oliveira, Joyce Cheng, Kelvin Chan, et al.
Cancer|April 21, 2015
Real-world chemotherapy treatment patterns in metastatic non-small cell lung cancer: Are patients undertreated?Adrian G Sacher, Lisa W Le, Anthea Lau, et al.
International Journal of Radiation Oncology, Biology, Physics|August 11, 2007
Use of palliative radiotherapy among patients with metastatic non-small-cell lung cancerJames A Hayman, Paul H Abrahamse, Indu Lakhani, et al.
JCO Oncology Practice|September 21, 2020
Real-World Costs of Azacitidine Treatment in Patients With Higher-Risk Myelodysplastic Syndromes/Low Blast-Count Acute Myeloid LeukemiaLee Mozessohn, Matthew C Cheung, Nicole Mittmann, et al.
Drugs & Aging|December 6, 2005
Trends in the treatment of acute myeloid leukaemia in the elderlyKathleen Lang, Craig C Earle, Talia Foster, et al.
Medicare & Medicaid Research Review|May 7, 2014
Cancer outcomes in low-income elders: is there an advantage to being on Medicaid?Siran M Koroukian, Paul M Bakaki, Cynthia Owusu, et al.
Journal of the National Cancer Institute|April 20, 2017
ResponseLee Mozessohn, Craig C Earle, David Spaner, et al.
Pageof 29

Showing results (61-70 of 288) with videos related to

Sort By:
Pageof 29
Journal of Thoracic Disease|October 18, 2021
Second and later-line erlotinib use in non-small cell lung cancer: real world outcomes and practice patterns overtime in CanadaKirstin Perdrizet, Rinku Sutradhar, Qing Li, et al.
Journal of the American College of Surgeons|February 21, 2009
Impact of patient age and comorbidity on surgeon versus oncologist preferences for adjuvant chemotherapy for stage III colon cancerMonika K Krzyzanowska, Meredith M Regan, Mark Powell, et al.
Leukemia & Lymphoma|February 11, 2020
Healthcare utilization in patients with higher-risk MDS/low-blast count AML treated with azacitidine in the 'real-world'Lee Mozessohn, Matthew C Cheung, Nicole Mittmann, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 8, 2020
High-Cost Patients and Preventable Spending: A Population-Based StudyClaire de Oliveira, Joyce Cheng, Kelvin Chan, et al.
Cancer|April 21, 2015
Real-world chemotherapy treatment patterns in metastatic non-small cell lung cancer: Are patients undertreated?Adrian G Sacher, Lisa W Le, Anthea Lau, et al.
International Journal of Radiation Oncology, Biology, Physics|August 11, 2007
Use of palliative radiotherapy among patients with metastatic non-small-cell lung cancerJames A Hayman, Paul H Abrahamse, Indu Lakhani, et al.
JCO Oncology Practice|September 21, 2020
Real-World Costs of Azacitidine Treatment in Patients With Higher-Risk Myelodysplastic Syndromes/Low Blast-Count Acute Myeloid LeukemiaLee Mozessohn, Matthew C Cheung, Nicole Mittmann, et al.
Drugs & Aging|December 6, 2005
Trends in the treatment of acute myeloid leukaemia in the elderlyKathleen Lang, Craig C Earle, Talia Foster, et al.
Medicare & Medicaid Research Review|May 7, 2014
Cancer outcomes in low-income elders: is there an advantage to being on Medicaid?Siran M Koroukian, Paul M Bakaki, Cynthia Owusu, et al.
Journal of the National Cancer Institute|April 20, 2017
ResponseLee Mozessohn, Craig C Earle, David Spaner, et al.
Pageof 29